Andreas Eberhorn - Dermapharm Holding Chief Officer
| DMP Stock | 37.80 0.10 0.26% |
Insider
Andreas Eberhorn is Chief Officer of Dermapharm Holding SE
| Age | 48 |
| Phone | 49 89 6 41 86 0 |
| Web | https://www.dermapharm.de |
Dermapharm Holding Management Efficiency
The company has return on total asset (ROA) of 0.119 % which means that it generated a profit of $0.119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3756 %, meaning that it generated $0.3756 on every $100 dollars invested by stockholders. Dermapharm Holding's management efficiency ratios could be used to measure how well Dermapharm Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Enno Spillner | Evotec SE | 53 | |
| Meredith Cook | ANI Pharmaceuticals | N/A | |
| Belen MD | Merck KGaA | 63 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Friederike Rotsch | Merck KGaA | 51 | |
| James Marken | ANI Pharmaceuticals | 60 | |
| Volker Braun | Evotec SE | N/A | |
| Peter Guenter | Merck KGaA | 61 | |
| Nikhil Lalwani | ANI Pharmaceuticals | 45 | |
| Dirk Toepfer | Merck KGaA | N/A | |
| Monika Conradt | Evotec SE | N/A | |
| Cord Dohrmann | Evotec SE | 59 | |
| Gerhard Schmitz | Merck KGaA | 60 | |
| Constantin Fest | Merck KGaA | 46 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Christopher Mutz | ANI Pharmaceuticals | 51 | |
| Stephen Carey | ANI Pharmaceuticals | 52 | |
| Krista Davis | ANI Pharmaceuticals | N/A | |
| Craig Johnstone | Evotec SE | 53 | |
| Gabriele Hansen | Evotec SE | N/A | |
| Matthias Evers | Evotec SE | 50 | |
Management Performance
| Return On Equity | 0.38 | |||
| Return On Asset | 0.12 |
Dermapharm Holding Leadership Team
Elected by the shareholders, the Dermapharm Holding's board of directors comprises two types of representatives: Dermapharm Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dermapharm. The board's role is to monitor Dermapharm Holding's management team and ensure that shareholders' interests are well served. Dermapharm Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dermapharm Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Britta Hamberger, Head Communications | ||
| HansGeorge Feldmeier, CEO Board | ||
| Christof Dreibholz, Chief Officer | ||
| Karin Samusch, Member Officer | ||
| Andreas Eberhorn, Chief Officer |
Dermapharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dermapharm Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.38 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 53.84 M | |||
| Shares Owned By Insiders | 65.04 % | |||
| Shares Owned By Institutions | 17.12 % | |||
| Price To Book | 4.69 X | |||
| Price To Sales | 2.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dermapharm Stock Analysis
When running Dermapharm Holding's price analysis, check to measure Dermapharm Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermapharm Holding is operating at the current time. Most of Dermapharm Holding's value examination focuses on studying past and present price action to predict the probability of Dermapharm Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermapharm Holding's price. Additionally, you may evaluate how the addition of Dermapharm Holding to your portfolios can decrease your overall portfolio volatility.